PDSB’s PDS01ADC Clinical Trial Yields 78% Response Rate in Tough-to-Treat Colorectal Cancer—Survival Nearly Doubles vs. Standard Approach
Market Chameleon (Wed, 15-Apr 11:09 AM)
PDS Biotech Shows Promising Phase 2 Results in Late-Line Prostate Cancer—Median PFS Reaches 9.6 Months
Market Chameleon (Wed, 28-Jan 10:34 AM)
